|
Country: United Kingdom
City: Oxford
IHTC:
Oxford Haemophilia Centre and Thrombosis Unit
Churchill Hospital
Headingtom, Oxford
OX3 7LJ
Oxford UK
Tel.: 44 1865 225 300
Fax: 44 1865 225 608
Email: paul.giangrande@ndm.ox.ac.uk
Website: www.medicine.ox.ac.uk
Director: Paul Giangrande
Responsible for training: Paul Giangrande
Fellowship logistics coordinator: Paul Giangrande
Year of IHTC designation: 1972
Areas of specialty: General hemophilia care; pediatrics; orthopedic surgery; laboratory diagnosis (not genetics).
DESCRIPTION OF TRAINING PROGRAM
Clinical activities: Our centre was the first clinical facility devoted to the care of people with bleeding disorders to be founded in the U.K. During the 1950s, pioneering work was carried out here by Prof. Gwynn Macfarlane and Dr. Rosemary Biggs. The centre is attached to the Nuffield Department of Clinical Medicine of the University of Oxford.
Our large centre provides regular treatment for approximately 250 patients with severe hemophilia each year, including both adults and children. We hold regular clinics for patients with orthopedic problems, and those with HIV infection and chronic hepatitis. There is also a dental unit within the centre. In addition, we offer a diagnostic outpatient facility for many other patients referred to us because of bleeding or thrombotic problems. Wider training in all aspects of haemostasis is available: for example, the unit is also responsible for the diagnosis and management of deep vein thrombosis (DVT). Training in molecular biology (e.g. mutation detection, antenatal diagnosis of haemophilia) can also be provided. The unit also accommodates the UK National Reference Centre for haemoglobinopathies (e.g. thalassaemia).
Laboratory activities/research: Diagnostic services to support the centre; collaborative clinical and diagnostic research with multiple other agencies. The training offered is tailored to the individual needs of each fellow, but we offer both clinical and laboratory training (including molecular biology).
Multidisciplinary activities/research: Orthopedic training is particularly strong, and is offered in conjunction with colleagues in the neighbouring Nuffield Orthopaedic Centre. We run regular clinics for the supervision of patients with problems related to HIV and chronic hepatitis.
Additional information: We are currently twinned with Doha ( Qatar) and Moscow ( Russia) through the WFH Twinning program.
DESCRIPTION OF IHTC FACILITIES
Location: You will find a lot of information about Oxford and our centre on our internet website (www.medicine.ox.ac.uk) and on: www.oxfordcity.co.uk. Oxford is an old university city, located 50 miles (80 km) northwest of London. The hemophilia centre is located n the Churchill Hospital, two miles east of the city centre.
Climate: Temperate. Typical maximum temperatures in summer are 25-30 °C, and the daytime minimum in winter is 0-5°C. Snow is unusual in winter, but rain may be expected in any season.
Accommodation (residence, meals, etc...): We can usually provide accommodation and food within the hospital at a very modest cost. Oxford is a cosmopolitan university city and you are likely to be able to meet people from your home country.
Transportation: There are very good road, rail and bus links with London and the airports. There are direct buses from both Heathrow and Gatwick airports every 30 minutes.
Language: English, some Spanish, some Russian, some Italian
Financial assistance: Dependent on WFH funds. Some additional financial support may be available in cases of special need.
Cost of living (per week): 450-500 USD
Communications tools for trainees: We have our own extensive library and offer access to computers with Internet and e-mail.
RELEVANT PUBLICATIONS BY IHTC STAFF
Sukhu K, Poovalingam V, Mahomed R, Giangrande PLF: Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clinical and Laboratory Haematology 25: 247-249 (2003)
Chapman-Sheath PJ, Giangrande PLF, Carr AJ: Arthroplasty of the elbow in haemophilia. (British) Journal of Bone and Joint Surgery 85: 1138-1140 (2003.
Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, Erhardtsen, Giangrande PLF. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10: 1-8 (2004).
Darby SC, Keeling DM, Spooner RJD, Giangrande PLF, Collins PW, Hill FG. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. Journal of Thrombosis and Haemostasis 2:1047-54 (2004)
Giangrande PLF: Blood products for hemophilia-past, present and future. BioDrugs 18: 225-234 (2004)
Giangrande PLF. Haemophilia B: Christmas disease. Expert Opinion in Pharmacotherapy 6:1517-24 (2005)
Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U for the European economic haemophilia study Group. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagulation and Fibrinolysis 16: 477-485 (2005).
Farrugia A, Ironside JW, Giangrande P. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty. Vox Sanguinis 89: 186-92 (2005)
|
